Literature DB >> 1378905

Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy.

N J Meropol1, L L Miller, E L Korn, L E Braitman, M L MacDermott, L M Schuchter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1378905     DOI： 10.1093/jnci/84.15.1201

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  25 in total

Review 1.  Recombinant methionyl granulocyte colony-stimulating factor (filgrastim): a new dimension in immunotherapy.

Authors:  G Schwab; T Hecht
Journal:  Ann Hematol       Date:  1994-07       Impact factor: 3.673

Review 2.  Optimizing the effectiveness of hematopoietic growth factors.

Authors:  D E Williams
Journal:  J Clin Immunol       Date:  1994-07       Impact factor: 8.317

3.  Racial Differences in Accepting Pegfilgrastim Onpro Kit (On-Body Injector) Use Among Cancer Patients.

Authors:  M W Saif; D W Hackenyos; M H Smith; P Healey; V Relias; K Wasif
Journal:  Clin Oncol (Las Vegas)       Date:  2019-02-25

Review 4.  Haemopoietic growth factors in paediatric oncology: a review of the literature.

Authors:  L M Wagner; W L Furman
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 5.  The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review.

Authors:  Gary H Lyman; Kim Allcott; Jacob Garcia; Scott Stryker; Yanli Li; Maureen T Reiner; Derek Weycker
Journal:  Support Care Cancer       Date:  2017-05-08       Impact factor: 3.603

6.  GM-CSF, carboplatin, doxorubicin: a phase I study.

Authors:  E A Poplin; D S Alberts; J J Rinehart; H O Smith; J A Neidhart; E M Hersh
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Effect of granulocyte-macrophage colony-stimulating factor on chemotherapy-induced oral mucositis in non-neutropenic cancer patients.

Authors:  E M Ibrahim; F A al-Mulhim
Journal:  Med Oncol       Date:  1997-03       Impact factor: 3.064

8.  Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth.

Authors:  Bikul Das; Roula Antoon; Rika Tsuchida; Shamim Lotfi; Olena Morozova; Walid Farhat; David Malkin; Gideon Koren; Herman Yeger; Sylvain Baruchel
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

9.  Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-alpha-2a in patients with advanced malignancies.

Authors:  S Wadler; H Haynes; R Schechner; A Rozenblit; P H Wiernik
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

10.  Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen.

Authors:  Rodolfo Mattioli; Cesare Gridelli; Javier Castellanos; Antonio Duque; Alfredo Falcone; Mauro Mansutti; Pam Bacon; Sue Lawrinson; Tomas Skacel; Ana Casas
Journal:  Clin Transl Oncol       Date:  2009-12       Impact factor: 3.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.